Amarin Corp. (AMRN) Tops Q1 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Amarin Corp. (AMRN) Reports Licensee HLS Therapeutics Inc. Files NDA for Vascepa with Health Canada
April 29, 2019 6:09 AM EDTAmarin Corporation plc (NASDAQ: AMRN) today announced that its licensee in Canada, HLS Therapeutics Inc. (HLS), has filed a New Drug Submission (NDS) with Health Canada for Vascepa® (icosapent ethyl) capsules. The NDS seeks an indication for promotion of Vascepa in Canada to reduce the risk of major adverse cardiovascular events (MACE) in statin-treated patients with elevated triglycerides and other risk factors. This is the first submission of Vascepa to Health Canada for any indication and, if approved, Vascepa will be the first drug approved in Canada for this important indication.
As previously... More
